In the commercial insurance market there can be wide variation in the cost of a service, driven by negotiating tactics and leverage of providers versus health plans. One technique to help drive utilization toward the lower unit cost providers is reference pricing. In reference pricing, the insurer typically identifies a low-cost provider and creates a benefit design in the health plan that ties payment for the service to that low-cost provider. The member must pick up the difference in cost if they choose to use a higher-cost provider. The impact tends to be that other providers must lower their prices to maintain market share and that patients gravitate toward greater use of the low-cost suppliers to minimize their out-of-pocket spending. The tactic gained widespread attention when CalPERS began to use it on joint replacement surgeries. Now research in JAMA Internal Medicine examines use of reference pricing in connection with diagnostic testing. (Int. Med. Article) The authors compared a large company that used reference pricing for laboratory tests with comparable members who were not in a plan using the technique. The employer had set maximum reimbursement at 60% of the distribution range for testing prices and had made pricing data available to members on a mobile app. The change appears to have worked well, although no quality data was reported, so we don’t know if care was impacted, but that is doubtful in the case of lab testing. Members covered by reference pricing were more likely to use lower cost labs. By the third year, the average price paid had declined 32%. The employer saved around $1.5 million over the three years and the employees saved $1.05 million in out-of-pocket spending. Lab testing is a relatively small portion of overall spending, but you can imagine that if it were more broadly applied to health services and products and even 15-20% price reductions were seen, a substantial reduction in health spending could occur.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
What do you get when you combine a company with a commodity business model, that out of desperation massively overpays for another company that has a commodity business model? $10...
July 27, 2022
The “stupid” model for health care venture capital investing is alive and well. Everside health, which operates primary care clinics and has grown by acquiring other failing health care businesses,...
July 26, 2022
Apparently not even a cute name can save you if you have a stupid business. I constantly bemoan the mis-application of capital and health care is Exhibit A. Olive, another...
July 26, 2022
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace